Well, the particular details of one’s PCa diagnosis (both clinical and genomic) are what should drive the first decision, which is active surveillance vs active treatment.

Once one’s clinical/genomic biomarkers cross one’s personal “Rubicon” (which will be different for every man) then the particular treatment selected should be chosen, in consultation with medical professionals, that aligns with one’s view of the potential side effects of a particular treatment upon your remaining years and how one would cope if, heaven forbid, they become a reality.

Of course, selecting the best physician/team with a transparent track record of side effect minimization is a big plus….also requiring research.

All the best,

Alan